

---

## Product Data Sheet

---

Product Name: BPI-9016M

Cat. No.: GC65966

### Chemical Properties

Cas. No. 1528546-94-2

Formula  $C_{25}H_{18}F_2N_4O_3$

M.Wt

460.43

Solubility

Storage

Store at -20°C

General tips

For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

### Background

BPI-9016M is a potent, orally active, and selective dual **c-Met** and **AXL** tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma<sup>[1][2]</sup>.

BPI-9016M (6.3-25 μM; 2 weeks) inhibited cell proliferation<sup>[2]</sup>.

BPI-9016M (12.5-50 μM; 24 hrs) induces accumulation of more tumor cells in the G1 phase<sup>[2]</sup>.

BPI-9016M (3.1-50 μM) reduces expression of c-Met, p-c-Met, p-AKT and p-ERK in the H1299 and A549 cells in a dose-dependent manner<sup>[2]</sup>.

The IC<sub>50</sub> of BPI-9016M in several lung adenocarcinoma cell lines (A549, H1299, H1650, H1975, HCC827, and PC-9 cells) as well as in primary lung adenocarcinoma cells are ranged from 5.3 μM to 27.1 μM<sup>[2]</sup>.

Cell Proliferation Assay<sup>[2]</sup>

Cell Line: A549 and H1299 cells

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

**Product Data Sheet**

---

Concentration: 6.3, 12.5, 25  $\mu$ M

Incubation  
Time: 2 weeks

Result: Colony formation was significantly inhibited in a dose-dependent manner.

### Cell Cycle Analysis<sup>[2]</sup>

Cell Line: A549 and H1299 cells

Concentration: 12.5, 25, 50  $\mu$ M

Incubation  
Time: 24 hours

Result: Induced accumulation of more tumor cells in the G1 phase.

BPI-9016M (60 mg/kg; p.o.; daily for 16 or 12 days) dramatically restrains tumor growth in PDX xenografts in NOD/SCID mice<sup>[2]</sup>.

Animal Model: NOD/SCID mice<sup>[2]</sup>

Dosage: 60 mg/kg

Administration: p.o.; daily for 16 or 12 days

Result: Dramatically restrained tumor growth in PDX xenografts in NOD/SCID mice.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA